This company has been acquired
Exscientia Future Growth
Future criteria checks 2/6
Exscientia is forecast to grow revenue at 39.8% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 27.4% |
| Revenue growth rate | 39.8% |
| Future return on equity | -15.1% |
| Analyst coverage | Low |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
Aug 08Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation
Jul 17
Exscientia: Too Much Pessimism
Jun 10Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 61 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 59 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 39 | N/A | N/A | N/A | 1 |
| 9/30/2024 | 17 | -151 | -119 | -103 | N/A |
| 6/30/2024 | 21 | -130 | -112 | -100 | N/A |
| 3/31/2024 | 20 | -129 | -122 | -105 | N/A |
| 12/31/2023 | 20 | -146 | -144 | -118 | N/A |
| 9/30/2023 | 24 | -144 | -195 | -166 | N/A |
| 6/30/2023 | 22 | -148 | -205 | -173 | N/A |
| 3/31/2023 | 26 | -141 | -119 | -88 | N/A |
| 12/31/2022 | 27 | -119 | -83 | -61 | N/A |
| 9/30/2022 | 25 | -100 | -46 | -28 | N/A |
| 6/30/2022 | 36 | -69 | 3 | 17 | N/A |
| 3/31/2022 | 29 | -59 | -23 | -13 | N/A |
| 12/31/2021 | 27 | -49 | -14 | -7 | N/A |
| 9/30/2021 | 27 | -36 | -7 | 0 | N/A |
| 6/30/2021 | 10 | -39 | -15 | -11 | N/A |
| 3/31/2021 | 13 | -24 | -31 | -27 | N/A |
| 12/31/2020 | 10 | -22 | -24 | -21 | N/A |
| 12/31/2019 | 9 | -6 | 5 | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EXAI's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if EXAI's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if EXAI's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EXAI's revenue (39.8% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: EXAI's revenue (39.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXAI is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/22 08:07 |
| End of Day Share Price | 2024/11/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exscientia plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Chris Shibutani | Goldman Sachs |
| Brendan Smith | TD Cowen |